US2013317111A1PendingUtilityA1

Desensitizing drug product

51
Assignee: ABSORPTION PHARMACEUTICALS LLCPriority: Jan 22, 2009Filed: Aug 6, 2013Published: Nov 28, 2013
Est. expiryJan 22, 2029(~2.5 yrs left)· nominal 20-yr term from priority
Inventors:Ronald Franklin GilbertAnthony C. CapomacchiaJody Helfend
A61P 15/00A61K 31/045A61K 47/10A61K 31/167A61K 9/0034A61M 11/001A61K 9/12A61P 15/10A61K 9/107A61P 23/02A61K 31/05
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising:
 an anesthetic agent selected from the group consisting of lidocaine, tetracaine, procaine, mepivacaine, bupivacaine, and etidocaine;   a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol selected from the group consisting of methanol, propanol, isopropyl alcohol, butanol, ethanol, menthol, and eugenol, and wherein the second melting point depressing agent is different from the first melting point depressing agent; and   a base;   wherein the base comprises an aqueous solution, the aqueous solution comprises a pH in the range of about 6.9 to about 8.9, and the pharmaceutical composition does not contain prilocalne.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the pH of the aqueous solution is about 6.9. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the pH of the aqueous solution is about 7.9. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the pH of the aqueous solution is about 8.9. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises a viscosity sufficient to permit delivery of the composition through a spray bottle. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the ratio of anesthetic agent to first melting point depressing agent is about 9:1 by weight. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the second melting point depressing agent comprises 10% by weight based on the total weight of the pharmaceutical composition. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the anesthetic agent is lidocaine, the first melting point depressing agent is thymol, and the second melting point depressing agent is ethanol. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the lidocaine comprises about 8.33% by weight based on the total weight of the pharmaceutical composition, the thymol comprises about 1.0% by weight based on the total weight of the pharmaceutical composition, and the ethanol comprises about 10% by weight based on the total weight of the pharmaceutical composition. 
     
     
         10 . A male genital desensitizing composition comprising:
 an anesthetic agent selected from the group consisting of lidocaine, tetracaine, procaine, mepivacaine, bupivacaine, and etidocaine;   a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol selected from the group consisting of methanol, propanol, isopropyl alcohol, butanol, ethanol, menthol, and eugenol, and wherein the second melting point depressing agent is different from the first melting point depressing agent; and   a base;   wherein the base comprises an aqueous solution, the aqueous solution comprises a pH in the range of about 6.9 to about 8.9, and the pharmaceutical composition does not contain prilocalne.   
     
     
         11 . The male genital desensitizing composition of  claim 10 , wherein the ratio of anesthetic agent to first melting point depressing agent is about 9:1 by weight. 
     
     
         12 . The male genital desensitizing composition of  claim 11 , wherein the second melting point depressing agent comprises 10% by weight based on the total weight of the pharmaceutical composition. 
     
     
         13 . The male genital desensitizing composition of  claim 11 , wherein the aqueous solution comprises a pH of about 7.9. 
     
     
         14 . The male genital desensitizing composition of  claim 11 , wherein the male genital desensitizing composition comprises a metered spray. 
     
     
         15 . A pharmaceutical composition comprising:
 an anesthetic agent selected from the group consisting of lidocaine, tetracaine, procaine, mepivacaine, bupivacaine, and etidocaine;   a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol selected from the group consisting of methanol, propanol, isopropyl alcohol, butanol, ethanol, menthol, and eugenol, and wherein the second melting point depressing agent is different from the first melting point depressing agent; and   an aqueous solution, wherein the aqueous solution comprises a pH in the range of about 6.9 to about 8.9, and the pharmaceutical composition does not contain prilocalne.   
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the ratio of anesthetic agent to a first melting point depressing agent is about 9:1 by weight. 
     
     
         17 . The pharmaceutical composition of  claim 15 , wherein the anesthetic agent is lidocaine, the first melting point depressing agent is thymol, and the second melting point depressing agent is ethanol. 
     
     
         18 . The pharmaceutical composition of  claim 16 , wherein the second melting point depressing agent comprises 10% by weight based on the total weight of the pharmaceutical composition. 
     
     
         19 . The pharmaceutical composition of  claim 16 , wherein the aqueous solution comprises a pH of about 7.9. 
     
     
         20 . The pharmaceutical composition of  claim 16 , wherein the pharmaceutical composition comprises a metered spray.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.